Lajos Pusztai, MD, PhD, of Yale Cancer Center, discusses study results on durvalumab in combination with olaparib and paclitaxel as neoadjuvant treatment in patients with high-risk HER2-negative stage II/III breast cancer. Compared with patients who received chemotherapy alone, the combination improved pathologic complete response, even in women with triple-negative breast cancer (Abstract CT011).
Grant A. McArthur, MBBS, PhD, of the Peter MacCallum Cancer Centre, discusses phase III results from a study of previously untreated patients with BRAF V600 mutation...
Edward B. Garon, MD, of the University of California, Los Angeles David Geffen School of Medicine, discusses KEYNOTE-189 trial findings that showed adding pembrolizumab to pe...
Nickolas Papadopoulos, PhD, of Johns Hopkins Medicine, discusses a first-of-its-kind prospective study that evaluated a screening blood test in more than 10,000 older women w...
Kimlin T. Ashing, PhD, of City of Hope National Medical Center, discusses analyses that showed neighborhoods with lower-income and minority populations had a greater number o...
Jennifer K. Litton, MD, of The University of Texas MD Anderson Cancer Center, discusses study results of talazoparib vs chemotherapy in patients with BRCA1/2-mutated...